Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ilaprazole - Il Yang

Drug Profile

Ilaprazole - Il Yang

Alternative Names: Aldenon; Aldenonc; IY-81149; IY-NT-R; IY-NT-T; Noltec; Yi Li An

Latest Information Update: 17 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Il-Yang
  • Developer Il-Yang; Livzon Pharmaceuticals; Takeda
  • Class Antiulcers; Benzimidazoles; Gastric antisecretories; Organic sulfur compounds; Pyridines; Pyrroles; Small molecules; Sulfoxides
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Gastro-oesophageal reflux; Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 27 Oct 2022 Il-Yang Pharm initiates a phase I pharmacokinetic trial in Healthy volunteers in South Korea (PO, Tablet) (NCT05617651)
  • 04 Oct 2022 Il-Yang Pharm plans a phase I pharmacokinetic drug interactions trial in Healthy volunteers (PO), in South Korea, in November 2022 (NCT05558150)
  • 22 Aug 2022 Il Yang initiates a phase I pharmacokinetic trial (In volunteers) in South Korea (PO) (NCT05509543)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top